20201109 Transgene BioInvent_SITC BT001_EN
Category: dates
Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
20201109 – TG4001+avelumab presentation poster SITC – EN
BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Poster BT-001 M. Semmrich et al. SITC 2020 Download the poster here Poster Presentation
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation
Transgene reports business update and end Q3 2020 financial position
20201105 Transgene Q3 business upradta EN
Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit
20201105 TG – Neoantigen summit presentation
Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
20201027 – TG4001+avelumab abstract data SITC – EN
Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
20201019 TG4001+avelumab SITC – EN
Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
20201015 – BT-001_SITC poster EN
Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
20201006 Transgene_NEC_BostonGene_Press_Release_final